发明名称 |
PEGylated mutated clostridium botulinum toxin |
摘要 |
The invention relates to a modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain resides in that it comprises (i) an extension of the chain on its N-terminus which has the structure —(C)n-(tag)m-(X)l— in the direction from the N- to the C-terminal end, wherein
C represents a cysteine residue,tag represents any tag andX represents the residue of any naturally occurring amino acid,n represents an integer from 1 to 50,m represents 0 or 1, andl represents 0 or an integer from 1 to 50,
and in that (ii) at least one of the cysteine residues in the extension of the chain is coupled to at least one chain of PEG. |
申请公布号 |
US8912140(B2) |
申请公布日期 |
2014.12.16 |
申请号 |
US201213624493 |
申请日期 |
2012.09.21 |
申请人 |
Merz Pharma GmbH & Co. KGaA |
发明人 |
Frevert Jürgen;Specht Volker |
分类号 |
A61K38/00;A61K39/00;C07K1/00;C12N9/96;C07K14/33 |
主分类号 |
A61K38/00 |
代理机构 |
Parker Highlander PLLC |
代理人 |
Parker Highlander PLLC |
主权项 |
1. A pharmaceutical composition comprising a modified botulinum toxin, the modified botulinum toxin comprising a natural heavy chain and a modified light chain, wherein the light chain comprises at least one and at most 20 amino acid residues occurring naturally at its N-terminus being mutated to a cysteine residue, and at least one chain of PEG coupled to at least one cysteine residue in said 20 amino acid residues at said N-terminus. |
地址 |
Frankfurt Au Main DE |